EA201991729A1 - ANTIBODIES TO TGF-BETA AND THEIR APPLICATION - Google Patents

ANTIBODIES TO TGF-BETA AND THEIR APPLICATION

Info

Publication number
EA201991729A1
EA201991729A1 EA201991729A EA201991729A EA201991729A1 EA 201991729 A1 EA201991729 A1 EA 201991729A1 EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A1 EA201991729 A1 EA 201991729A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tgf
antibodies
beta
application
antibody
Prior art date
Application number
EA201991729A
Other languages
Russian (ru)
Inventor
Гари Шапиро
Кевин Брауэн
Патрик ФИНН
Ричард С. Грегори
Рао Кодури
Фэн Лю
Наталья Малкова
Парминдер Манку
Джек Р. Поллард
Хуавэй Цю
Йоахим Тайльхабер
Кристофер Винтер
Марчелла Юй
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201991729A1 publication Critical patent/EA201991729A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем изобретении предусмотрено улучшенное панспецифичное антитело к TGF-β для лечения состояний, опосредованных TGF-β, в том числе аутоиммунных заболеваний, фиброзных состояний и форм рака. Также предусмотрены способы и пути применения антитела в сочетании с другими иммуномодулирующими средствами, такими как антитело к PD-1.The present invention provides an improved pan-specific antibody to TGF-β for the treatment of conditions mediated by TGF-β, including autoimmune diseases, fibrotic conditions and forms of cancer. Also provided are methods and routes for using the antibody in combination with other immunomodulatory agents, such as an anti-PD-1 antibody.

EA201991729A 2017-01-20 2018-01-19 ANTIBODIES TO TGF-BETA AND THEIR APPLICATION EA201991729A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305061 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Publications (1)

Publication Number Publication Date
EA201991729A1 true EA201991729A1 (en) 2019-12-30

Family

ID=58018036

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991729A EA201991729A1 (en) 2017-01-20 2018-01-19 ANTIBODIES TO TGF-BETA AND THEIR APPLICATION

Country Status (3)

Country Link
EP (1) EP3571227A1 (en)
EA (1) EA201991729A1 (en)
WO (1) WO2018134681A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
WO2020012383A1 (en) 2018-07-10 2020-01-16 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
MX2021000347A (en) 2018-07-11 2021-04-19 Scholar Rock Inc High-affinity, isoform-selective tgfî²1 inhibitors and use thereof.
PE20220279A1 (en) 2019-01-30 2022-02-25 Scholar Rock Inc SPECIFIC INHIBITORS OF THE LTBP COMPLEX OF TGF BETA AND USES THEREOF
JP2023511255A (en) 2020-01-11 2023-03-17 スカラー ロック インコーポレイテッド TGF-β inhibitor and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
EP4121163A1 (en) * 2020-03-19 2023-01-25 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (en) * 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
CN104177497B (en) 2005-02-08 2018-01-16 根茨美公司 For TGF β antibody
KR101970025B1 (en) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Antibodies and other molecules that bind b7-h1 and pd-1
EA032327B1 (en) * 2013-03-20 2019-05-31 Джензим Корпорейшн Methods for treating osteogenesis imperfecta
BR112016005408B1 (en) 2013-09-13 2023-03-21 Beigene Switzerland Gmbh ANTI-PD1, F(AB) OR F(AB)2 ANTIBODIES AND REFERRED USE ANTIBODY FOR TREATMENT OF CANCER OR VIRAL INFECTION
TWI681969B (en) * 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody Molecules of PD-1 and Their Uses
KR102513870B1 (en) * 2014-10-14 2023-03-23 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
CN108136001B (en) * 2015-04-03 2022-07-29 佐马技术有限公司 Cancer treatment with TGF-β inhibitors and PD-1 inhibitors

Also Published As

Publication number Publication date
EP3571227A1 (en) 2019-11-27
WO2018134681A8 (en) 2019-10-10
WO2018134681A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
EA201991729A1 (en) ANTIBODIES TO TGF-BETA AND THEIR APPLICATION
MX2023002588A (en) Anti-tgf-beta antibodies and their use.
EA202092410A1 (en) CONJUGATES OF CAMPTOTHETCIN WITH PEPTIDE
EA201891732A1 (en) BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201891983A8 (en) COMBINED THERAPY BY ANTIBODIES TO CD73
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
EA201990208A1 (en) CHIMER ANTIGENIC RECEPTORS AIMED AT BCMA AND WAYS OF THEIR APPLICATION
EA201891992A1 (en) CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
EA202091130A1 (en) LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
EA201790288A1 (en) ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, PHARMACEUTICAL COMPOSITION AND APPLICATION
MX2019005426A (en) Anti-lag3 antibodies and antigen-binding fragments.
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA201790248A1 (en) MEDIA-ANTIBODY COMPOSITIONS AND METHODS FOR THEIR RECEIVING AND APPLICATION
EA201890443A1 (en) BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
PE20161390A1 (en) MULTI-SPECIFIC ANTIBODIES
EA202191785A1 (en) ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION
EA201692539A1 (en) ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES
UA123202C2 (en) ANTIBODY TO TAU-PROTEIN AND ITS APPLICATION
EA201792561A1 (en) ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION
EA201691521A1 (en) ANTIBODIES TO INTERLEUKIN-21
EA201892716A1 (en) Antibody to Coagulation Factor XI